Business context and reporting period
Roman DBDR Tech Acquisition Corp. (Nasdaq: DBDR; units DBDRU; warrants DBDRW) filed an unaudited Form 10-Q for the quarter ended March 31, 2021. The filing describes a blank-check company seeking a business combination; it had not begun operating or generating revenue. The filing’s registrant is Roman DBDR Tech Acquisition Corp., notwithstanding the request metadata naming GPGI, Inc.
Financial results and position
| Metric | Quarter / period-end value |
|---|---|
| Revenue | None; no operating revenue reported. |
| Operating and formation costs | $1.45 million for Q1 2021. |
| Net income | $8.93 million, driven primarily by a $10.31 million noncash gain from the decrease in fair value of warrant liabilities. |
| Cash flow | $189,310 used in operating activities; ending cash outside the trust was $414,305. |
| Trust assets | $236.28 million in cash and marketable securities, primarily money market funds investing in U.S. Treasury securities. |
| Liquidity | Working capital deficit of $505,403, excluding stated franchise and income taxes payable of $50,000. Current assets were $831,011 and current liabilities $1.34 million. |
| Debt and other obligations | No long-term debt reported. Deferred underwriting fee payable was $8.10 million, due only if a business combination closes. Warrant liabilities totaled about $17.14 million. |
| Margins / EPS | Margins are not meaningful without revenue. EPS disclosures conflict: the statement reports $0.44 for redeemable Class A shares, while the EPS footnote reports $0.00; nonredeemable common EPS is reported as $0.92. |
Changes versus prior period
Compared with December 31, 2020, trust assets increased from $236.22 million to $236.28 million. Cash outside the trust decreased from $603,615 to $414,305, and accounts payable and accrued expenses rose from $98,112 to $1.34 million. Warrant liabilities fell from $27.46 million to $17.14 million; the resulting fair-value gain materially increased reported Q1 income. The filing provides no prior-year quarterly operating comparison.
Outlook, transaction, and risks
- On April 19, 2021, after quarter-end, the company agreed to combine with CompoSecure. The announced transaction contemplated approximately $853 million of CompoSecure equity value and approximately $1.2 billion of pro forma enterprise value, subject to closing conditions.
- Planned financing included $45 million of Class A stock subscriptions and $130 million of CompoSecure senior exchangeable notes bearing 7% interest and exchangeable at $11.50 per share. The agreement also contemplated up to 7.5 million earnout shares or units, subject to stock-price thresholds.
- Closing conditions included stockholder and member approvals, regulatory clearance, completion of the financings, minimum net tangible assets of $5,000,001, a minimum cash test, and limits on CompoSecure net indebtedness. The agreement could be terminated in specified circumstances, including failure to close by December 31, 2021, with a possible extension to January 31, 2022.
- The SPAC’s combination deadline was May 10, 2022; failure to complete a transaction would generally require redemption of public shares and liquidation. Public warrants could expire worthless.
- The company said it believed available resources were sufficient through a business combination or the deadline, but reported limited operating cash and a working-capital deficit. In May 2021, the Sponsor agreed to provide up to $1.5 million in loans; as of March 31, no amount was outstanding.
- Management said COVID-19 could adversely affect the company’s financial position or target search, but the impact was not determinable. The filing identified a material weakness in internal control over financial reporting related to warrant accounting and said disclosure controls were not effective at a reasonable-assurance level; management and the board planned a review to remediate weaknesses.
Important facts for investors to verify
- Confirm the CompoSecure merger’s final terms, financing, redemptions, closing conditions, and subsequent outcome; the transaction described here was pending at the filing date.
- Reconcile the conflicting EPS figures for redeemable Class A shares and confirm the correct balance-sheet and cash figures where the filing differs slightly across sections.
- Assess the warrant fair-value estimates and the status of remediation of the disclosed accounting-control weakness.
- Verify liquidity, Sponsor loan availability, and the ability to fund transaction costs if the deal is delayed or does not close.
- The filing’s cover page checks “No” for having filed all required Exchange Act reports during the applicable period; verify the filing status and any related explanation.